Vir Biotechnology is an American biotechnology company based in San Francisco, California.
COVID-19
Vir Biotechnology is a participating organization in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.[1]
On April 7, 2020, Vir Biotechnology and GlaxoSmithKline announced that they had entered an agreement to collaborate on SARS-CoV-2 monoclonal antibody and COVID-19 vaccine products.[2]
Partners
Vir Biotechnology is partnered with:[3]
- Alnylam Pharmaceuticals
- Bill & Melinda Gates Foundation
- Brii Biosciences
- Gilead Sciences
- GlaxoSmithKline
- Institute for Research in Biomedicine (IRB)
- Oregon Health & Science University (OHSU)
Investors
Investors in Vir Biotechnology include:[4][2:1]
- Alta Partners
- Altitude Life Science Ventures
- ARCH Venture Partners
- Bill & Melinda Gates Foundation
- GlaxoSmithKline
- Section 32[5]
- SoftBank Vision Fund
External links
ACTIV. National Institutes of Health (NIH). Retrieved April 1, 2022, from http://archive.today/2022.01.11-042823/https://www.nih.gov/research-training/medical-research-initiatives/activ ↩︎
Chowdhry, A. (2020, April 7). GlaxoSmithKline Invests $250 Million In Vir Biotechnology As Part Of A Strategic Deal. Pulse 2.0. https://web.archive.org/web/20230710162820/https://pulse2.com/glaxosmithkline-invests-250-million-in-vir-biotechnology-as-part-of-a-strategic-deal/ ↩︎ ↩︎
Development Pipeline. Vir Biotechnology. Retrieved June 5, 2023, from https://web.archive.org/web/20230605065123/https://www.vir.bio/pipeline/#collab ↩︎
Venture Round - Vir Biotechnology - 2017-01-06 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 10, 2023, from https://www.crunchbase.com/funding_round/vir-biotechnology-series-unknown--4be38a50 ↩︎
About. S32. Retrieved July 29, 2023, from https://www.s32.com/#about ↩︎
